Field Note from AGBT 2026: Genomics Is Dead. Long Live Genomics
AGBT 2026 did not feel like a year of fireworks. It felt like something more important: a year in which the genomics ecosystem quietly grew up.
There were fewer "one big thing" moments. No single platform announcement seemed to dominate the field. Instead, the signal came from the accumulation of many smaller, more pragmatic advances: better workflows, clearer roadmaps, stronger benchmarks, falling costs, methylation moving from promise to product, spatial becoming mainstream, and multiomics increasingly becoming the default mental model rather than a futuristic add-on.
In a quick DeciBio pulse of 52 attendees, the most common takeaway was not Roche, Illumina, spatial, AI, methylation, or cost per gigabase — although all of those mattered. The top theme was the "long tail": the flood of smaller talks, announcements, and observations that collectively shaped the conference. That, to me, was the real story of AGBT 2026. The field is no longer waiting for one breakthrough to define the next era. The next era is being assembled piece by piece.
The winners showed receipts
Roche stood out because it did what customers increasingly want platform companies to do: show real data, real benchmarks, and real economics. In a more crowded sequencing landscape, claims are no longer enough. Buyers want to know what is real, what is shipping, what it costs, and when the roadmap matters.
Illumina also had a strong "gets it done" presence. TruPath and a set of pragmatic updates reinforced the company's continued ability to translate scale, installed base, and customer understanding into usable product evolution. It was not necessarily a reinvention story. It was an execution story. And in this market, execution may be the more valuable story.
That is a broader lesson for the industry. As genomics becomes clinical and translational infrastructure, the product is no longer just the chemistry, the instrument, or the readout. The product is the workflow. The product is confidence. The product is proof.
Spatial is no longer emerging
Spatial omics felt less like a frontier category and more like part of the mainstream life sciences toolkit. The conversation has shifted from "Is this exciting?" to "How do we make it easier, cheaper, more reproducible, and more integrated into real workflows?"
That transition matters. Technology categories become strategically important when they stop depending on evangelism and start depending on execution. Spatial is entering that phase. The next competitive frontier will be less about who can generate the most beautiful images and more about who can turn those images into scalable biological insight.
The epigenome may finally be having its real moment
Every few years, someone declares "the year of the epigenome." Historically, that has often been more aspiration than reality. But this year felt different.
Methylation was everywhere: Syndex, Watchmaker / TAPS, nanopore-based approaches, and broader interest in epigenomic readouts as a way to access biology that DNA sequence alone cannot capture. The important shift is that methylation is increasingly moving from scientific intrigue to usable product architecture.
That is a big deal. If genomics tells us what could happen, epigenomics gets us closer to what is happening. For oncology, early detection, aging, developmental biology, and cell state biology, that difference is strategically profound.
AI was everywhere — and nowhere
AI had an undertone in many conversations, but it rarely felt like the headline. That is probably healthy.
The most interesting uses of AI in this field may not be branded as AI at all. They will show up as better interpretation, better assay design, better workflow automation, better data integration, better clinical reporting, and better prioritization of what to test next.
In other words, AI is becoming less of a product category and more of an operating layer. The companies that win may not be the ones shouting "AI" the loudest. They may be the ones using it to make complex biology more usable.
Multiomics is becoming the new default
One of the best lines from the farewell dinner was: "Genomics is dead. Long live genomics."
That is not a eulogy. It is a promotion.
Genomics is not disappearing. It is becoming the backbone of a broader multiomic view of biology: DNA, RNA, methylation, protein, spatial context, cell state, and eventually longitudinal clinical data. The market is gradually moving from measuring more bases to understanding more biology.
This is why proteomics momentum at AGBT felt meaningful. The future is not simply cheaper sequencing. It is richer biological measurement. Cost per gigabase will keep falling, and that matters. But the strategic question is increasingly: what new biology becomes actionable when measurement becomes cheaper, multimodal, and computationally interpretable?
The bat talk was a reminder of why this matters
Emma Tilling's "bat talk" stood out because it pulled the field back to something fundamental: genomics is not just an industrial platform market. It is a way to understand life.
That may sound soft, but it is strategically important. The best markets in life sciences are built when deep scientific curiosity eventually collides with scalable technology and real-world use cases. Conservation, aging, evolution, cancer, rare disease, infectious disease, drug discovery — these are not separate stories. They are different expressions of the same underlying shift: biology is becoming measurable at unprecedented resolution.
The strategic read-through
My biggest takeaway from AGBT 2026 is that genomics is entering a more mature phase. Not less exciting. More useful.
The field is moving from spectacle to systems. From platform claims to proof. From single-modality thinking to multiomic integration. From beautiful demos to workflow adoption. From "look what we can measure" to "look what decisions we can change."
That is exactly what should happen as a technology category matures.
For years, the genomics industry has been framed around disruption: faster, cheaper, longer, deeper. Those vectors still matter. But the next phase will be defined by translation: into clinical workflows, drug development, population health, agriculture, conservation, and everyday decision-making across biology.
AGBT 2026 may not be remembered as the year of one giant announcement. It may be remembered as the year the field looked less like a collection of competing technologies and more like an emerging operating system for biology.
And that may be the bigger story.